DBD vs DXCM · P/E 28, rev $3.75B vs P/E 63, rev $4.03B
Diebold Nixdorf, Incorporated (DBD) versus DexCom Inc (DXCM) — a side-by-side from cached financials, not a winner call.
Diebold Nixdorf, Incorporated (DBD) is a software - application company listed on US.
DexCom Inc (DXCM) is a medical devices company listed on US.
Latest reported DBD revenue for 2024-12-31 was $3.75B. Net income was -$14.5M. Revenue was up 130.3% from 2023-12-31 to 2024-12-31. DBD currently screens at market cap $2.82B and trailing P/E 28.1.
Latest reported DXCM revenue for 2024-12-31 was $4.03B. Net income was $576.2M. Revenue was up 11.3% from 2023-12-31 to 2024-12-31. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
DBD currently screens at market cap $2.82B and trailing P/E 28.1. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
Not investment advice. Open the DBD and DXCM stock pages for the full models.
Not investment advice.